Assessment of the management and outcome of neutropenia in paediatric haemato-oncology inpatients at Kenyatta National Hospital
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20233427Keywords:
Management, Neutropenia, Outcome, Pediatric haemato-oncologyAbstract
Background: Neutropenia is a common complication among the haemato-oncology pediatric patients. Children who develop such complications are prone to bacterial infections which further predispose them to death. This study aimed at improving the practice of management of neutropenia in children with the view of reducing pediatric haemato-oncology mortality.
Methods: We retrospectively reviewed medical records of paediatric haemato-oncology inpatients aged 13 years and below, who developed neutropenia during treatment at Kenyatta National Hospital. A data abstraction form was used to collect data from 113 medical records of patients admitted between 1st January 2020 and 31st December 2020. Data were analyzed using R to obtain descriptive and inferential statistics using a 95% confidence interval.
Results: Boys constituted most of the cases assessed. The median (IQR) age at admission was 6 (4, 10) years. Leukaemias were more common than lymphomas. Acute lymphocytic leukaemia (59%) and Hodgkin’s lymphoma (4%) were the most and least frequently diagnosed haemato-oncology cancers. Most patients were diagnosed during the induction stage, 47 (42%) and had febrile neutropenia 59 (52%). Vaccination and bone marrow suppression histories were poorly documented. Thirty-three (29%) patients were reported to have succumbed during their treatment. G-CSF prescription was statistically significantly associated (p=0.045) with the survival status (death or alive) of patients, particularly at the induction stage (p=0.007).
Conclusions: Neutropenia management in KNH is done as per protocol, with room to improve on history taking. Although 29% of the children succumbed within the course of treatment, the majority (71%) of the patients were discharged.
References
Dale D. How I diagnose and treat neutropenia. Curr Opin Haematol. 2016;23(1):1-4.
Punnapuzha S, Edemobi P, Elmoheen A. Febrile Neutropenia. StatPearls. 2021.
Mohammed H, Yismaw M, Fentie A, Tadesse T. Febrile neutropenia management in pediatric cancer patients at Ethiopian tertiary care teaching hospital. BMC Res Notes. 2019;12(1):528.
Escrihuela-Vidal F, Laporte J, Albasanz-Puig A, Gudiol C. Update on the management of febrile neutropenia in haematologic patients. Revist Españ Quimioter. 2019;32(Suppl 2), 55.
Muchela M. Patterns of antibiotic prescription during febrile episodes in pediatric patients with cancer at the Kenyatta National Hospital. University of Nairobi. 2020.
Davis K, Wilson S. Febrile neutropenia in pediatric oncology. Pediatr Child Health. 2020;30(3):93-7.
Rivera-Salgado D, Valverde-Munoz K, Ávila-Agüero M. Febrile neutropenia in cancer patients: management in the emergency room. Revist Chilena Infectol. 2018;35(1):62-71.
Cashen A, Van Tine B. The Washington Manual of Haematology and Oncology Subspecialty Consult; (Lippincott Manual Series). 4th edn. Kindle Edition. Washngton. Wolters Kluwer Health; 2016.
Kenyatta Health Information System (2021).
Mutua I, Mwika P. Incidence of childhood cancers at a tertiary hospital in Kenya: 2009-2019. Acta Sci Pediatr. 2020;8(3).
Macharia L, Mureithi M, Anzala O. Cancer in Kenya: types and infection-attributable. Data from the adult population of two National referral hospitals (2008-2012). AAS Open Res. 2019;1:25.
de Castro Carpeño J, Gascón-Vilaplana P, Casas‑Fernández‑de Tejerina AM, Antón‑Torres A, López‑López R, Barnadas‑Molins A, et al. Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study. Mol Clin Oncol. 2015;3(3):725-9.
Palukuri N, Yedla R, Bala S, Kuruva S, Chennamaneni R, Konatam M, et al. Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer. South Asian J Cancer. 2020;9(01):04-6.
American Cancer Society (n.d.). Growth Factors and Similar Medicines for Myelodysplastic Syndromes. Available from: https://www.cancer.org/cancer/ myelodysplastic-syndrome/treating/growth-factors.html. Accessed on 13 May 2023.
